PT - JOURNAL ARTICLE AU - Bouchareb, soumaya AU - Touil, Imen AU - Keskes, Nadia AU - Ben Rhouma, Chaima AU - Nemsi, Ella AU - Romdhane, Raja AU - Knani, Jalel AU - Boussoffara, Leila TI - Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem AID - 10.1183/13993003.congress-2020.1280 DP - 2020 Sep 07 TA - European Respiratory Journal PG - 1280 VI - 56 IP - suppl 64 4099 - http://erj.ersjournals.com/content/56/suppl_64/1280.short 4100 - http://erj.ersjournals.com/content/56/suppl_64/1280.full SO - Eur Respir J2020 Sep 07; 56 AB - Introduction: The use of inhaled corticosteroids (ICS) would be potentially effective in reducing symptoms and the number of exacerbations in non-cystic fibrosis (N-CF) bronchiectasis.Aims: To evaluate the efficacy and safety of ICS in adults with N-CF bronchiectasis.Methods: Retrospective study including 125patients with N-CF bronchiectasis in stable condition. These patients were divided in two groups: the first group (G1) consists of 70 patients who received ICS and the second group (G2) consists of 55 patients who did not receive ICS.Results: We recruited 125 patients in this study. In the G1, the number of patients hospitalized for acute exacerbation and the number of hospitalizations in the intensive care unit were higher (p <0.05). Also, the number of re-hospitalization in the year following the prescription of ICS was significantly higher in G1(p=0.013). In fact, the average hospitalization rate increased from 0.7 ± 1.04 to 1.34 ±1.66 after ICS therapy. Respiratory function was clearly improved after ICS therapy, in fact the mean FEV increased from 1.38 to 4.62 l/min. The bacteriological investigation revealed a bronchial infection with Pseudomonas Aeroginosa in 8 patients undergoing inhaled corticosteroid therapy, whereas it was only 2 patients in G2 but without a statistically significant difference. The biological inflammatory syndrome was more evident in the G1 (p >0.05).In G1, fifteen patients (21.4%) received oxygen therapy and / or non-invasive ventilation at home versus one patient in G2 (p = 0.17).The number of deaths was greater in the G1 (p = 0.17).Conclusion: ICS can contribute to the improvement of lung function in patientswithnonN-CF bronchiectasis. This benefit remains controversial despite the presence of chronic airway inflammationFootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1280.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).